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Carriers of the fragile X premutation (FPM) have CGG trinucleotide repeat expansions of between 55 and 200 in the
5′-UTR of FMR1, compared to a CGG repeat length of between 5 and 54 for the general population. Carriers were
once thought to be without symptoms, but it is now recognized that they can develop a variety of early
neurological symptoms as well as being at risk for developing the late onset neurodegenerative disorder fragile
X-associated tremor/ataxia syndrome (FXTAS). Several mouse models have contributed to our understanding of
FPM and FXTAS, and findings from studies using these models are summarized here. This review also discusses
how this information is improving our understanding of the molecular and cellular abnormalities that contribute to
neurobehavioral features seen in some FPM carriers and in patients with FXTAS. Mouse models show much of the
pathology seen in FPM carriers and in individuals with FXTAS, including the presence of elevated levels of Fmr1
mRNA, decreased levels of fragile X mental retardation protein, and ubiquitin-positive intranuclear inclusions.
Abnormalities in dendritic spine morphology in several brain regions are associated with neurocognitive deficits in
spatial and temporal memory processes, impaired motor performance, and altered anxiety. In vitro studies have
identified altered dendritic and synaptic architecture associated with abnormal Ca2+ dynamics and electrical
network activity. FPM mice have been particularly useful in understanding the roles of Fmr1 mRNA, fragile X mental
retardation protein, and translation of a potentially toxic polyglycine peptide in pathology. Finally, the potential for
using these and emerging mouse models for preclinical development of therapies to improve neurological
function in FXTAS is considered.
Keywords: CGG trinucleotide repeat, FMR1, FMRP, Fragile X premutation, FXTAS, Intranuclear inclusions, Mouse
models, RNA toxicityIntroduction
The Fragile X mental retardation 1 gene (FMR1) is located
on the long arm of the X-chromosome at Xq27.3 and
codes for the fragile X mental retardation protein (FMRP),
which is necessary for normal brain development and syn-
aptic plasticity [1-5]. The fragile X gene carries a variable
number of CGG repeats in the 5′-UTR of between 5 and
55 in most individuals (modal value 32 to 33; Figure 1).
However, due to instability of the repeat across genera-
tions, there are large numbers of individuals who carry an
expanded CGG repeat of between 55 and 200. These* Correspondence: rfberman@ucdavis.edu
1Department of Neurological Surgery, Room 502C, UC Davis, 1515 Newton
Court, Davis, CA 95618, USA
Full list of author information is available at the end of the article
© 2014 Berman et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.individuals are referred to as fragile X premutation (FPM)
carriers, and occur in the general population with an esti-
mated frequency of 1 in 209 females and 1 in 430 males
[6,7]. Further expansion of the CGG repeat to greater than
200 in the offspring of FPM carriers leads to the full muta-
tion, silencing of FMR1 expression and fragile X syndrome
(FXS), the major known inherited cause of intellectual
disability [4,8].
Carriers with 55 to 200 CGG repeats were originally
thought to be clinically unaffected. However, it is now
known that they can develop a variety of neurological
symptoms, including memory problems, deficits in
executive function, depression, anxiety, and problems
with numerical processing and magnitude estimates
[3,10,11]. They are also at risk for developing the latel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Most individuals in the general population have between 5 and 54 CGG trinucleotide repeats in the 5′-UTR of FMR1. Repeat length
in the fragile X premutation range is 55 to 200, resulting in an elevation in FMR1 mRNA levels, a moderate decrease in FMRP and an increased risk of
developing FXTAS. Repeat size in the full mutation is >200; FMR1 transcription is silenced due to DNA hypermethylation, and the absence of FMRP
results in fragile X syndrome. (Adapted from [9].) FMRP, fragile X mental retardation protein; FXTAS, fragile X-associated tremor/ataxia syndrome.
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tremor/ataxia syndrome (FXTAS). Major symptoms of
FXTAS include tremor, ataxia, impairments in execu-
tive function and memory, and cognitive decline and
dementia in some patients [12,13]. Neuropathology
includes brain atrophy, ventricular enlargement, loss of
Purkinje neurons, white matter disease, disruption of
nuclear lamin A/C architecture and accumulation of
intranuclear protein inclusions [5,14].
The chances of developing FXTAS increase dramatic-
ally with age, with approximately 45.5% of male and
16.5% of female FPM carriers over the age of 50 develop-
ing FXTAS [15]. Indeed, FXTAS may be one of the more
common causes of tremor and ataxia in older adults [16].
Besides age, the risk factors that lead to the development
of FXTAS in some, but not all, FPM carriers are unknown,
but are likely to include CGG repeat length, additional
genetic mechanisms and environmental factors (for ex-
ample, environmental toxins, other illnesses [3]). Identify-
ing the risk factors for FXTAS is particularly important
and animal models will undoubtedly play a major role in
this area of research.
Because of the increase in the number of people reach-
ing the age of 65, it is likely that the number of cases of
FXTAS will increase accordingly, further highlighting
the importance of research on FXTAS [16]. Therefore, it
is important to understand the underlying pathology in
FXTAS, to establish its developmental time course, and
to develop rational treatments to delay or halt progres-
sion of disease and improve neurological function.Review
Pathogenesis in affected FPM carriers and in FXTAS
Pathology in affected FPM carriers and in individuals
with FXTAS is thought to be the result of RNA toxicity
caused by 2- to 8-fold elevated levels of CGG-repeat-
bearing FMR1 mRNA. As depicted in Figure 2A, elevated
Fmr1 mRNA with a CGG repeat expansion is thought to
sequester proteins critical for normal cell function, result-
ing in pathology. This hypothesis is supported by the find-
ing that inclusions isolated from postmortem brain tissue
from patients with FXTAS contain FMR1 mRNA and over
30 proteins, many critical for normal cell function, such as
lamin A/C, γH2AX, Sam 68, drosha, Ku86 and hnRNPA2
[17-19]. However, recent findings have suggested an
additional model for toxicity, as depicted in Figure 2B, in
which a potentially toxic polyglycine-containing peptide is
produced as the result of a CGG repeat-mediated non-
ATG translation (RAN) mechanism [20]. Research using
animal models has provided much of the evidence
supporting these theories as presented in this review.Development of mouse models
Several mouse models have been developed to study the
FPM and FXTAS. These models show much of the path-
ology associated with CGG repeat expansions on FMR1.
Table 1 compares pathology seen in FXTAS with that
reported in CGG knock-in (KI) mouse models, includ-
ing molecular, histological and some behavioral deficits.
However, no models have been completely successful in
Figure 2 Potential mechanisms of CGG-repeat RNA toxicity in FMP carriers. (A) Protein sequestration model: RNA binding proteins are
sequestered through their interactions with the expanded CGG-repeat RNA. These proteins can in turn recruit other proteins. The net result of
sequestration of these proteins is that they are unavailable to carry out their normal functions and critical cellular processes are thereby altered or
blocked. (? -Sequestration of SAM68 by CGG expanded repeats is indirect, presumably through protein-protein interactions). (B) Toxic polypeptide
model: The 43S translation initiation complex stalls near the CGG repeat hairpin formed on the FMR1 RNA. This promotes the repeat-associated
non-AUG translation of FMR1 mRNA using a near-AUG start site. This results in a frame shift and the production of polyglycine- and/or
polyalanine-containing polypeptides that somehow interfere with normal cell function or may be directly toxic. FMRP, FMRP, fragile X mental
retardation protein; ORF, open reading frame; polyA, polyalanine; polyG, polyglycine.
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or individuals with FXTAS. An important example is
the absence of any reports of obvious tremor in current
mouse models, a defining neurological feature of FXTAS.
Therefore, it is acknowledged at the outset that current
mouse models only partially recapitulate features of the
FPM and FXTAS. The mouse models described below
have been developed to study specific aspects of disease
associated with CGG repeat expansions; each offers
advantages and limitations, and each has already
provided important insights into disease mechanisms.
The Dutch mouse
The study of FXS and FXTAS has been greatly facilitated
by the development of animal models that mimic much
of the pathology associated with these disorders. TheTable 1 FXTAS compared to the CGG knock-in mouse model
Pathology Human FXTAS
CGG trinucleotide repeat
length
55 to 199 CGG repeat length, repeat instability
Elevated FMR1 mRNA
expression
Increased 2- to 8-fold
Fragile X mental
retardation protein levels
Reduced in several brain regions
Motor impairments Tremor/ataxia, postural sway, parkinsonism
Cognitive Impairments Poor working memory, anxiety, depression, soci
Intranuclear inclusions Neurons and astrocytes, highly correlated with
length, frequency increases with age
Adapted from [21].first mouse model of FXTAS and the FPM was a CGG
KI mouse model from the Willemsen laboratory in the
Netherlands, the so-called Dutchmouse (CGGdut KI). This
mouse model was generated by replacing the native mur-
ine CGG repeat eight trinucleotides in length (CGG8)
within the endogenous Fmr1 gene with a human CGG98
repeat by homologous recombination in embryonic stem
cells [22]. Importantly, while minimal changes to the murine
Fmr1 promoter were made when the targeting construct
containing the human (CGG)98 repeat was generated, the
region flanking the repeat in the human FMR1 was in-
cluded. These CGG KI mice show moderate instability of
repeat length upon paternal and maternal transmission,
with both small expansions and contractions (that is, typ-
ically fewer than 10 repeats) [22-24]. These CGGdut KI
mice have been bred onto a C57BL/6 J background overCGG knock-in mouse
70 to 300 CGG repeats, modest repeat instability
Increased 1.5- to 3-fold
Reduced in several brain regions
Impaired on rotarod and ladder rung task
al phobia Spatial memory deficits, altered anxiety-like behaviors
CGG repeat Neurons and astrocytes, related to length of CGG
repeat, frequency increases with age
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ranging from 70 to greater than 300 CGG repeats [21,22].
Although expected, based on silencing of FMR1 expres-
sion in FXS, no increased methylation of the Fmr1 gene
has been found even with longer CGG repeat expansions
(for example, >300). As described below, these mice models
exhibit much of the pathology seen in affected FPM
carriers and in FXTAS, including increased expression
of Fmr1 mRNA, decreased FMRP, ubiquitin-positive
intranuclear inclusions (Figure 3) and evidence for
motor and spatial processing deficits [21].The National Institutes of Health mouse
A second KI mouse was developed at the National Insti-
tutes of Health with an initial CGG118 tract [26,27]. The
CGGnih KI mice were generated using a different strat-
egy from the CGGdut mice. They were developed using a
targeting construct in which exon 1 of the mouse gene
was retrofitted with two adjacent but incompatible Sfi I
sites. The repeats were generated in vitro in such a way
that they were flanked by the appropriate Sfi I sites. This
allowed the CGG repeats to be inserted into the mouse
locus in the correct orientation and in such a way as to
make minimal changes to the mouse flanking sequence.
As a result of this strategy, the CGGnih mouse retains
the translational TAA stop codon just upstream of the
CGG118 repeat that is present in the endogenous mur-
ine gene but not the human gene. As with the CGGdut
mice, the CGGnih mice show elevated Fmr1 mRNA
levels, decreased FMRP levels, moderate intergenera-
tional expansions, no methylation (even when repeatFigure 3 Ubiquitin-positive intranuclear inclusions in neurons and ast
punctate intranuclear inclusions in pyramidal neurons in motor cortex (A),
Intranuclear inclusions (red) were labeled by immunofluorescence for ubiq
Bergmann glia (green) for GFAP. In (B), note an intranuclear inclusion in an
(Adapted from [25]).numbers were >300) and ubiquitin-positive intranuclear
inclusions [26].
Similarities and differences between CGGdut and CGGnih
knock-in models
The two CGG KI mouse models show similarities as well
as some differences [26,28]. Both models show several-
fold increases in levels of Fmr1 mRNA and a reduction
in brain levels of FMRP that is inversely related to CGG
repeat length. However, they differ in that the reduction
in FMRP in the CGGdut KI mouse (20% to 30%) is typic-
ally much less than that reported in the CGGnih KI
(>50%). Ubiquitin-positive intranuclear inclusions are found
in both models, but are more common in neurons and as-
trocytes in the CGGdut KI model [20]. Inclusions in CGGdut
KI mice are widespread in the brain, including the hippo-
campus, cortex, cerebellum, olfactory bulb, superior and
inferior colliculi, and hypothalamus [24]. Purkinje cell loss
is seen in postmortem tissue from FXTAS brains, as well
as in the CGGnih KI mouse, but has not been reported in
the CGGdut KI mouse [26]. Behaviorally, there is evidence
for memory impairment in both models [29,30], but the
CGGdut KI mouse shows increased anxiety [31] whereas
the CGGnih KI mouse shows decreased anxiety [30]. Both
models show modest intergenerational repeat instability.
Neither model, however, reliably shows large expansions
in the length of the CGG repeat tract seen with maternal
transmission in FXS, and no methylation or silencing of
Fmr1 expression has been reported in either model. This
difference between humans and mice in the frequency of
large germline expansions may be due to differences in
the length of the perigametic interval in males of bothrocytes of CGGdut knock-in mice. White arrows point to red
cortical astrocytes (B) and Bergmann glia in cerebellum (C).
uitin, neurons (green) for Kv2.1 potassium channels, and astrocytes and
adjacent neuron (arrowhead). Nuclei were stained with DAPI.
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females (decades) [32]. The levels of the proteins involved
in generating or preventing expansions during the periga-
metic interval could also contribute to these differences [33].
The reasons for differences between the two models in
FMRP reduction, Purkinje cell loss and the frequency of
intranuclear inclusions are unclear given that both were
generated with CGG repeat sequences that differed only
by approximately 20 repeats. However, the cloning strat-
egy used to make these mouse lines differed in that the
CGGnih KI mouse retains a greater region of the mouse
5′UTR flanking the CGG repeat, including a TAA stop
codon that is not present in the CGGdut KI mouse. The
absence of this stop codon in the CGGdut KI may allow
RAN translation of a novel polyglycine protein that
appears to contribute to CGG repeat toxicity in human
cell lines and in a Drosophila model [20]; conversely, its
presence in the CGGnih KI may block this CCG RAN
translation. The ability to compare the pathology between
the two mouse models represents an important and
powerful tool for understanding the mechanisms of
disease in the FPM and in FXTAS.
Ectopic expression of an expanded CGG90 in transgenic mice
In order to determine whether ectopic expression of an
expanded CGG90 repeat causes neurodegeneration inFigure 4 Ectopic expression of a CGG90 repeat results in Purkinje cel
is, L7Fmr1) showing normal distribution of Purkinje cells in the Purkinje cell
mouse. (C) Selective Purkinje cell loss in 32-week-old mouse expressing a C
L7CGG90Fmr1). (D) Purkinje cell loss in shown at higher magnification in L7
Purkinje cell layer. (Adapted from [34]).the cerebellum, transgenic mice (L7-CGG90-Fmr1) were
developed in which expression was spatially restricted to
cerebellar Purkinje neurons using the L7 promoter [34].
In these mice, the CGG90 repeat was upstream of either
Fmr1 or enhanced green fluorescent protein (EGFP) cDNA
(L7-CGG90-Fmr1, L7-EGG90-EGFP), with control mice
expressing Fmr1 or EGFP but without a CGG90 repeat
expansion (L7-Fmr1, L7-EGFP). Significant Purkinje cell
loss was observed in 32-week-old L7-CGG90-Fmr1 and
L7-CGG90-EGFP mice compared to wild-type (WT) lit-
termates or L7-Fmr1/L7-EGFP mice (Figure 4). Ubiquitin-
positive intranuclear inclusions were found in Purkinje
neurons of both the L7-CGG90-Fmr1 and L7-CGG90-
EGFP lines, but were not found in either WT littermates
or the L7-Fmr1 or L7-EGFP control lines. Lack of inclu-
sions in control mice, in addition to their presence in the
L7-CGG90-EGFP line, demonstrates an essential role for
the CGG repeat expansion in inclusion formation, and
that expressed CGG repeat containing RNA is sufficient
to induce inclusions. These Purkinje neurons stained posi-
tive for the 20S core complex of the proteasome, Hsp40,
and Rad23B. Interestingly, staining was negative for Purα,
hnRNPA2/B1, Tau and α-synuclein - all proteins that have
been reported in human intranuclear inclusions in human
FXTAS [18]. Motor performance on the rotarod was also
impaired in mice expressing the CGG90 repeat comparedl loss. (A) Cerebellum of control mouse without a CGG90 repeat (that
layer. (B) Higher magnification of the Purkinje cell layer in control
GG90 repeat under the L7 Purkinje cell-specific promoter (that is,
CGG90Fmr1 mouse. gl, granule cell layer; ml, molecular layer; pcl,
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similar impairment was seen in 20- and 40-week-old
mice. These results provide evidence that CGG repeat
mRNA expression is sufficient to cause Purkinje
neuron dysfunction and loss similar to that reported in
FXTAS [35].
Neuropathological observations to date demonstrate a
connection between formation of intranuclear inclusions
and cell death. While it is tempting to speculate that the
formation of inclusions is the cause of cell loss, such a
conclusion is contingent upon understanding what the
functional ramifications are when proteins and their inter-
acting partners are sequestered within an inclusion body.
A Drosophila model ectopically expressing premutation-
length CGG repeats showed a neurodegenerative eye
phenotype and Hsp70/ubiquitin-positive inclusions [36].
A subsequent genetic screen showed that CELF1
(CUGBP1), when ectopically expressed, was able to sup-
press the neurodegenerative eye phenotype [37]. CELF1
was also shown to directly interact with hnRNPA2/B1,
known to be present in inclusions of patients with FXTAS
[18]. CELF1 is up-regulated overall in the presence of CUG
repeats >50, contributing to the mis-regulation of mRNA
splicing and translation and the muscle atrophy and weak-
ness observed in muscular dystrophy type 1, the disease for
which its involvement is best known [38-40]. CELF1 is
therefore predicted to be one potential modifier of CGG
repeat-mediated neurodegeneration. Preliminary findings in
mice show modulation of neuropathological phenotypes
previously reported in the L7CGG90 transgenic mice
when the expression of CELF1 is altered (Zalewski et al.
Abstracts of the 1st Premutation Meeting, Perugia,
Italy, 2013). Such findings support an RNA toxicity
mechanism (see Evidence for current disease models
section), specifically that the sequestration of such
proteins within an inclusion inhibits their normal function,
leading to dysregulation (at least at the level of RNA
processing) in the cell and, over time, cell death.
Fmr1 overexpressing mice
Levels of FMR1 mRNA bearing an expanded CGG are
elevated several fold in premutation carriers and in pa-
tients with FXTAS, supporting the hypothesis that path-
ology is the result of FMR1 mRNA toxicity. However,
the possibility exists that toxicity could be due to either
the CGG repeat itself, elevated FMR1 mRNA independ-
ent of the repeat expansion, or both. In a Drosophila
model of FXTAS, high expression levels of a CGG60
repeat causes formation of ubiquitin-positive inclusions
and neurodegeneration in the retina in a dosage- and
repeat length-dependent manner, whereas moderate
expression of the repeat allele results in little pathology.
These findings support the notion that overall abun-
dance of a CGG repeat molecule may be important forgenerating a pathological phenotype [36]. To investigate
the potential deleterious effects produced by overexpres-
sion of FMR1 mRNA with a normal CGG repeat length,
transgenic mice that overexpress FMR1 mRNA bearing
a normal length CGG29 repeat have been generated [41].
The CGG29 transgenic mouse was obtained by pronuclear
injection of a construct containing the human FMR1
cDNA with 29 CGG repeats under control of a SV40/T7
promoter. This model results in a 20- to 100-fold increase
in FMR1 mRNA in all tissues studied (for example, liver,
cerebral cortex and cerebellum). However, these animals
did not show significant differences from WT mice in
general activity or anxiety-related behaviors in open-field
tests. These results suggest it is expression of the ex-
panded CGG repeat that is primarily responsible for
pathology, and not overexpression of Fmr1 mRNA per se.
Other transgenic mice overexpressing FMR1 mRNA have
been made using a yeast artificial chromosome (YAC)
containing the full-length human FMR1 gene. These YAC
mice show a 2- to 3-fold increase in expression of FMR1
mRNA and a 10- to 15-fold increase in FMRP compared
with control littermates [42,43]. When crossed with a
knock-out (KO) mouse model of FXS that lacks FMRP,
some of the pathological features of FXS were reversed.
Importantly there were no changes in overall brain
morphology at the light microscopic level due to overex-
pression of mRNA or protein. However, overexpression in
otherwise WT mice (that is, not KO mice) also resulted in
some abnormal behaviors, including decreased activity,
increased anxiety-like behavior and enhanced startle
response. Although the authors attributed these behavioral
effects to overexpression of FMRP, the high levels of Fmr1
mRNA could also have contributed to the behavioral
effects [43].
Yeast artificial chromosome transgenic mouse models of
the FPM
YAC transgenic mouse lines have also been generated to
study CGG repeat instability [44]. These mice were gen-
erated using a CGG92 allele isolated from an adult male
premutation carrier, a CGG repeat length that would be
expected to show expansion to the full mutation when
transmitted through the female germ line in humans.
The CGG92 region, including several hundred base pairs
of flanking sequence, was cloned into a YAC and puri-
fied YAC DNA was injected into FVB/N mouse oocytes
and then transplanted into foster mothers. A line of
offspring (line TG296) carrying a CGG90 repeat were
then identified. Although not yet well characterized,
these YAC mice show modest intergenerational CGG
repeat instability, expansion and contraction of one to
three trinucleotides across generations. There was no
influence of parental sex or age on transmission of the
repeat.
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Continued development of new mouse models to study
the FPM and FXTAS has resulted in generation of a
doxycycline-inducible mouse line with a CGG99 repeat
RNA under control of a doxycycline-responsive promoter
(R. Hukema, Abstracts of the 1st Premutation Meeting,
Perugia, Italy, 2013). Preliminary findings in this mouse
show the presence of doxycycline-inducible ubiquitin-
positive intranuclear inclusions in the hippocampus and
cerebellum. This mouse is being used to determine critical
periods for the onset of pathology as well as to help define
molecular targets for development of future treatments.
Brain and cellular pathology
The description of brain pathology associated with FPM
and FXTAS is limited by the availability of tissue for
analysis. As a result, virtually all that is known about
such pathology has come from studies of postmortem
tissue from premutation carriers who developed FXTAS,
and from findings in animal models. To date there have
not been any published studies on brain pathology seen
in FPM carriers without FXTAS, including if and when
intranuclear inclusions and cell loss (for example, Pur-
kinje neurons) may be occurring.
Intranuclear inclusions
The hallmark histopathology in FXTAS includes the
presence of ubiquitin-positive inclusions in neurons and
astrocytes that is widespread throughout the brain. As a
further parallel between human FXTAS and the CGG KI
mice, both show the presence of ubiquitin-positive intra-
nuclear inclusions in many regions of the brain [24-26,45].
The CGGdut KI develops intranuclear inclusions in neu-
rons in the cerebral cortex, olfactory nucleus, parafascicu-
lar thalamic nucleus, medial mammillary nucleus and
colliculus inferior, cerebellum, amygdala and pontine nu-
cleus cortex, hippocampus, hypothalamus, and in granule
cells of the cerebellum (Figure 3) [24,28]. Inclusions in the
dentate gyrus of the hippocampus are evident as early as
12 weeks of age [29]. The number of inclusions in glia, in-
cluding astrocytes and Bergmann glia, and their distribu-
tion in the brain are more limited, and not as numerous
as found in postmortem FXTAS brain tissue [14,25]. In
addition, the size of the inclusions correlates significantly
with the age of CGGdut KI mice, with smaller inclusions
found in younger mice. Interestingly, the gradual in-
crease in the size of the inclusions and the percentage
of ubiquitin-positive neurons appear to parallel the
progressive development of the neurological phenotype of
FXTAS in humans [16]. Brain regions showing the pres-
ence of intranuclear inclusions correlate with the clinical
features in patients with symptomatic FXTAS. Import-
antly, inclusions are not limited to the nervous system,
and are found in both human FXTAS and in the CGGdutKI mouse in a variety of other tissues, including pancre-
atic, thyroid, adrenal gland, gastrointestinal, pituitary
gland, pineal gland, heart and mitral valve. Inclusions were
also found in the testes, epididymis and kidney of patients
with FXTAS, but not in the KI mice [46]. Therefore,
FXTAS should be considered a multi-organ disease.
Systematic analysis of these inclusions shows the presence
of more than 20 proteins including ubiquitin, molecular
chaperone Hsp40, 20S proteasome complex, DNA
repair-ubiquitin-associated HR23B factor and SAM-68,
DGCR8, and DROSHA [18,19,24,47-49]. The inclusions
also contain FMR1 mRNA, but surprisingly not FMRP
[18]. Similar studies on the protein composition of inclu-
sions found in CGG mouse models have not been carried
out, but it is already apparent that there are some similar-
ities between the inclusions in FXTAS and mouse models,
including the presence of ubiquitin, SAM68, DGCR8 and
lamin A/C, as well as several differences [18,19,24,27,47,50].
Purα has been detected in intranuclear inclusions in a Dros-
ophila model of the premutation and overexpression can
suppress CGG repeat-mediated neurodegeneration. How-
ever, purα has not yet been detected in inclusions in murine
models and evidence for its presence in human inclusions
is inconclusive [18,50]. Similarly, hnRNP-A2/B1 are found
in the intranuclear inclusions in FXTAS [18], but little or
none has been found in CGG KI mice [34]. Additional
research on the composition of intranuclear inclusions in
FXTAS and mouse models would clearly be of value.
Cell loss
An important neuropathological finding in human FXTAS
is the presence of Purkinje cell degeneration [35]. This has
also been observed in the CGGnih KI mouse, and in mice
with an ectopic CGG90 repeat expansion whose expres-
sion is limited to cerebellar Purkinje neurons as shown in
Figure 4 [26,34]. However, the generalized brain atrophy,
including enlarged ventricles, that has been reported in
some patients with FXTAS has not been systematically ex-
amined in any of the existing mouse models. Such studies
need to be carried out using structural magnetic reson-
ance imaging and quantitative stereology of neurons in
brain regions known to be affected in FXTAS, to establish
whether similar pathology also occurs in mouse models.
White matter disease
FXTAS is also characterized by white matter disease, in-
cluding loss of glial cells, enlarged astrocytes, spongiosis
and pallor in subcortical and cerebellar white matter,
including in the middle cerebellar peduncle [14,35,51].
Additional pathology in FXTAS is seen on T2-weighted
magnetic resonance images that show hyperintensities in
white matter tracts, including the middle cerebellar ped-
uncle [52]. Tractography studies using diffusion-weighted
magnetic resonance imaging have provided additional
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tracts in FXTAS, including the middle cerebellar peduncle,
superior cerebellar peduncle and corpus callosum, that
was not found in premutation carriers without FXTAS
[51]. As yet, these important findings have not been
systematically examined in mouse models of the FPM or
FXTAS, and there are no published reports of white
matter pathology or degeneration of major fiber tracts in
animal models.
Dendrite and dendritic spine morphology
Studies of Golgi-stained neurons have also revealed ultra-
structural changes in dendrites and dendritic spines in
both CGGdut and CGGnih KI mice [30,53]. The CGGdut KI
mouse shows fewer dendritic branches proximal to the
soma, reduced total dendritic length and longer dendritic
spines on basilar, but not on apical dendrites in pyramidal
neurons in the primary visual cortex. Neither total den-
dritic spine density, nor the density for specific dendritic
spine subtypes (that is, stubby, mushroom, filipodial) dif-
fered between WT and KI mice. Dendrite and dendritic
spine morphology has also been examined in CGGnih KI
mice in several brain regions, including the medial pre-
frontal cortex, hippocampus and basal lateral amygdala. In
all three brain regions, the branching complexity of apical
and basilar dendrites was significantly lower and spines
were longer in KI mice compared to WT, consistent with
findings in the CGGdut KI mouse. However, in the CGGnih
KI mouse, dendritic spine density was generally increased
in all three brain regions in contrast to the CGGdut KI
mouse, which did not show changes in spine density. It is
interesting to note that longer dendritic spines found
in the cortex of CGG KI mice have also been reported in
Golgi studies of postmortem tissue in FXS [54,55] and in
Fmr1 KO mice [56,57], whereas the reduction in dendritic
branching complexity in CGG KI mice was not found in
the Fmr1 KO mouse [56]. The reasons for these similar-
ities and differences are unknown but should be further
investigated. To our knowledge, dendritic branching and
spine morphology have not been examined in postmortem
tissues from carriers of the FPM or patients with FXTAS.
Lamin A/C disruption
Expression of expanded CGG RNA also results in the
widespread disruption of lamin A/C proteins with asso-
ciated abnormalities in nuclear envelope morphology
in vitro and in vivo [58,59]. Lamins A/C are intermediate
filament proteins that that line the inner nuclear mem-
brane where they help maintain the shape and mechan-
ical integrity of the nucleus [60]. They are generated
from a single LMNA gene by alternative splicing, and
mutations have been linked to a variety of neurodegenera-
tive diseases. Cells deficient in lamin A/C show decreased
survival and defective response to DNA damage [61].These observations suggest that FXTAS may result in
a functional laminopathy. This is consistent with recent
findings that demonstrate that laminopathy diseases, in-
cluding restrictive dermopathy and Hutchinson-Gilford
progeria syndrome, result in increased levels of reactive
oxygen species and accumulation of DNA damage [62].
Moreover, several proteins involved in telomere main-
tenance [63-65] are present in the intranuclear inclu-
sions characteristic of FXTAS (for example, lamin A/C,
Ku80, γH2AX) [18] and could account for shorter
telomere length demonstrated in patients with FXTAS
[66,67]. Shorter telomere length could also contribute to
the reduce life expectancy associated with longer CGG
repeat lengths in patients with FXTAS [14,25]. While
disruption of nuclear lamin A/C architecture has been
reported in mouse embryonic fibroblasts from CGGdut
KI mice, studies in mice examining Ku80 and γH2AX
have not been carried out [58].
Mitochondrial dysfunction
Several symptoms reported in FXTAS share some com-
monalities with mitochondrial respiratory chain enzyme
deficiencies, including gait ataxia, white matter disease,
peripheral neuropathology, muscular weakness and neuro-
psychiatric disorders [68]. Mitochondrial dysfunction
occurs in FPM and FXTAS and has been examined in
cultured skin fibroblasts and in frozen frontal cortex
from postmortem brain tissue samples from premuta-
tion carriers with or without FXTAS [68]. Decreased
NAD- and FAD-linked oxygen uptake rates have been
found in premutation carriers compared to controls. In
addition there is reduced expression of the mitochon-
drial protein MnSOD, an antioxidant enzyme, and nitra-
tion of ATPB, a putative marker for nitrative/oxidative
stress is elevated approximately 2-fold in FPM and
FXTAS compared to controls, indicating mitochondrial
dysfunction. Mitochondrial dysfunction has also been
found in cultured hippocampal neurons isolated from
CGGdut KI mice as early as 4 days in vitro (DIV) [69].
Density and mobility were assessed by time-lapse im-
aging of mitochondria labeled with Mitotracker Red
CMXRos, and oxygen consumption was estimated by
measuring the rate of change of dissolved O2 in the
medium surrounding the cultured hippocampal neurons
using a Seahorse Bioscience extracellular flux analyzer.
CGGdut KI mice showed reduced density of mitochon-
dria in proximal neurites (that is, within 25 μm of
soma), as well as significantly reduced mobility com-
pared to WT mice. Neurons from CGGdut KI mice also
showed high basal oxygen consumption rates and evi-
dence for increased protein leakage and higher ATP
production. The authors suggested that these abnormal-
ities in mitochondrial distribution and bioenergetics
may contribute to previous reports of lower viability
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pal neurons [70] as well as to reduced dendritic branch-
ing and altered spine morphology in CGG KI mouse
neocortex [30,53]. It is important to consider the possi-
bility that mitochondrial disease may contribute to the
risk for premutation carriers to become symptomatic or
to develop FXTAS, and this potential link should be
explored in futures studies in using mouse models.
Molecular findings
Fmr1 mRNA and FMRP
Both the CGGdut KI and the CGGnih KI mice have
proven to be very useful models to study the molecular
aspects of the expanded CGG repeat. The brains of these
two mouse lines show small (10% to 30%) to moderate
(>50%) reductions in FMRP, respectively, despite the fact
that 2- to 3-fold elevated levels of Fmr1 mRNA are
found [23,26,28,71-73]. These results parallel to a great
extent what is found in some human premutation car-
riers and in patients with FXTAS as outlined in Table 1
[21]. The linear correlation between FMR1 mRNA levels
and the repeat size in FPM and in patients with FXTAS
[72,74] has also been found in brain tissue from the
CGGdut KI mouse [73]. Entezam et al. were able to show
a direct relationship between CGG-CCG repeat size and
Fmr1 mRNA levels in the brains of the CGGnih KI mice,
although the number of mice studied for the different
repeat sizes was limited [26]. The cellular mechanism
underlying the increase in Fmr1 mRNA levels is un-
known, but could be due to a feedback mechanism
resulting from reduced levels of FMRP. Mechanisms
underlying reduced FMRP include impeded migration of
the 40S ribosomal complex along the expanded CGG
tract, as well as the use of an alternative internal ribo-
some entry site for initiation of translation. An internal
ribosome entry site has been identified in the 5′UTR of
FMR1 mRNA [75].
Fmr1 splice variants and FMRP isoforms
The FMR1 gene has 17 exons with alternative splice sites
on exons 12, 14, 15 and 17 that result in the expression
of multiple FMRP isoforms [76-78]. The splicing pattern
of these isoforms is of interest as, in some isoforms, the
truncation or absence of functional domains would sug-
gest a change in FMRP functional properties including
its selection of protein partners and mRNA targets and
its cellular localization. For instance, the N-terminus of
FMRP harbors a nuclear localization signal and FMR1
mRNA binding activity is driven by two K Homology
domains encoded by exons 8 to 12 and an RGG box do-
main in exons 14 to 15 [79]. Additionally, a nuclear export
signal is localized to exon 14 and serine phosphorylation
sites involved in translational regulatory activity of FMRP
as well as methylation sites are also localized to exon 15.The transcript levels of these isoforms are developmen-
tally regulated in the brain of the WT C57BL/6 mouse
strain [77], the same strain used to construct the CGGdut
KI mouse model [24]. Isoform distributions were similar
across 11 different brain regions with the exception of the
hippocampus and the olfactory bulb. Although to date no
information is available on isoform distribution in the
CGGdut KI mouse, the polyadenylation state of Fmr1 tran-
scripts, which can be informative for the stability and the
translational efficiency of the mRNA, has been investi-
gated in these mice. The CGGdut KI mouse exhibits an
increased population of short poly(A) mRNAs, usually
indicative of inefficiently translated transcripts, compared
to WT [80]. It would be interesting to know whether
particular mRNA isoforms are thus more efficiently
translated than others in the CGGdut KI background.
Expression profiling
Dysfunction of the GABAergic system has been reported
in CGGdut KI mice [81]. Specifically, overexpression of
genes for several GABAA receptor subunits (for example,
α1,3,4; β2; γ2) and proteins involved in GABA metabolism
(gad1, ssadh) has been observed in the cerebellum, but
not the cortex, of CGGdut KI mice, which could be related
to the motor phenotype observed in FXTAS [82,83]. In
Fmr1 KO mice, expression was decreased for some of
these same genes (for example, gad1, ssadh), but the rea-
sons for this difference are unclear. Microarray analysis in
the cerebellum of transgenic mice that overexpress human
FMR1 with a normal range CGG29 repeat has also been
carried out, but there were no clear changes in the
GABAergic system compared to controls. Among GABA-
related genes, only up-regulation of the GABAA receptor-
associated protein-like 2 (Gabarapl2) gene was observed
[41]. These results provide additional support that path-
ology in CGG KI mice, at least in the GABA system, is
due to expansion of CGG repeats rather than increased
mRNA levels, given that FMR1 mRNA levels were
increased 20 to 100 times in these transgenic mice com-
pared with those of WT littermates. However, other
changes were seen in the transcriptome of these mice
that could be a consequence of an overabundance of
FMR1 mRNA. Interestingly, the two most altered genes
in the transcriptome were transthyretin (Trt), and serpina3,
putative biomarkers for Alzheimer’s disease [84,85]. Ser-
pina3, a serine protease inhibitor that is released during
inflammatory responses, was up-regulated and may reflect
the increased prevalence of autoimmune disease (for
example, lupus, multiple sclerosis, fibromyalgia, thyroid
disease) in females with the FMR1 premutation [86].
Transthyretin, a transport protein for retinol and thyroxine
thought to contribute to thyroid hormone homeostasis,
was down-regulated [87]. Although speculative, reduced
transcription could be related to the hypothyroidism
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two microRNAs, mir-181a-1 and let-7 appeared up-
regulated in CGG mice. Up-regulation of Let-7 miRNA
has been also been reported in a Drosophila model of
FXTAS [88]. This is important because several miRNAs
are up-regulated in human premutation carriers [89],
although they differed from those observed in CGG
transgenic mice [41].
Electrophysiological findings
GABA/glutamate imbalance and abnormal synaptic
network activity
The origin of pathology in FXS and in some FPM car-
riers, with or without FXTAS mutations, is the presence
of a CGG repeat expansion on FMR1, raising the possi-
bility that some of the same molecular pathways could
be affected in both disorders, and those associated with
glutamatergic signaling in particular [1,74,90,91]. This is
in spite of differences in the causal molecular underpin-
nings in the disorders, and specifically the lack of FMRP
expression in FXS versus the overexpression of FMR1
mRNA in the FPM and FXTAS. In fact, the dysregula-
tion in excitatory and inhibitory neurotransmission in
the central nervous system of FXS KO mice has been
the subject of active investigation during the last decade,
and evidence has recently surfaced that suggests a
similar dysregulation in the CGG KI mice [1,90,91].
Hippocampal CGGdut KI neurons in vitro show a devel-
opmental defect in connectivity and impaired dendritic
growth observed at 7 and 21 days DIV. There is also a loss
of cell viability, also suggestive of a neurodegenerative
component to the FPM [70]. Interestingly, in the same
neurons, the expression of the vesicular GABA and glu-
tamate transporters VGAT and VGLUR1, respectively, is
reduced at 21 DIV, but not at 7 DIV. These alterations are
associated with a 4- to 8-fold increase in Fmr1 mRNA and
an approximately 50% decrease in FMRP.
Abnormal patterns of electrical activity are also seen
in vitro in hippocampal neurons from CGGdut KI mice, in-
cluding enhanced clustered burst (CB) firing. Specifically,
hippocampal neurons cultured from CGGdut KI mice
display CB electrical spiking activity and abnormal patterns
of spontaneous synchronous Ca2+ oscillations under basal
culture conditions [92]. The principal mechanisms contrib-
uting to these neuronal network defects in basal electrical
activity appear to be associated with a gain of function in
type I metabotropic glutamate receptors (mGluRs) and/or
a loss of function in GABAA receptor signaling. This con-
clusion is supported by data indicating that: the type I mGluR
receptor agonist 3,5-Dihydroxyphenylglycine (DHPG), but
neither NMDA nor AMPA receptor agonists, increased
CB firing patterns in WT neurons with increased spike
rate and mean burst duration similar to those observed in
FPM hippocampal neurons; selective mGluR1/5 antagonists7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate
ethyl ester (CPCCOEt) and 2-methyl-6-(phenylethynyl)
pyridine hydrochloride (MPEP) abrogated abnormal
electrical activity in FPM neurons; FPM astrocytes have
impaired glutamate uptake [69,93]; WT cultures ex-
posed to the astrocyte glutamate transport competitive
antagonist DL-threo-β-benzyloxyaspartic acid produced
electrical firing patterns indistinguishable from those of
CGGdut KI neurons; GABAA receptor block with picro-
toxin generated CB firing behavior observed in CGGdut
neurons; and the allosteric GABAA receptor enhancer
allopregnanolone essentially restored WT electrical
spiking patterns.
These functional deficits are directly pertinent to the
altered patterns of neuronal complexity reported earlier
using the same in vitro CGGdut KI model [70]. Neuronal
network activity is essential for normal neuronal migra-
tion, dendritic growth and synaptic plasticity, processes
mediated by spatially and temporally orchestrated intra-
cellular Ca2+ signals. Therefore, the abnormal CB elec-
trical activity and abnormal patterns of spontaneous Ca2+
oscillations observed in hippocampal neurons from
CGGdut KI mice are likely to contribute, at least in part, to
impaired dendritic growth and synaptic architecture.
Hippocampal synaptic plasticity
Deficits in processing spatial and temporal information
have been reported in FPM carriers and in patients with
FXTAS, suggesting hippocampal-associated pathology.
In order to fully characterize the CGG KI mouse and to
provide clues to which brain regions mediate these
cognitive deficits (for example, hippocampus), in vitro
studies of synaptic plasticity in acute hippocampal slices
isolated from CGGdut KI mice and WT mice have been
carried out. Specifically long-term potentiation (LTP) of
synaptic transmission and long-term synaptic depression
(LTD) in CGGdut and WT mice have been examined.
The results demonstrated that the magnitude of LTP
was significantly lower in CGG KI mice compared to
WT mice, indicating impaired synaptic plasticity. Simi-
larly, LTD, whether induced by low-frequency electrical
stimulation (1 Hz) or bath application of the mGluR1/5
agonist DHPG, was also limited in CGG KI mice versus
WT mice. These findings implicate loss of neuroplasti-
city in the hippocampus in the spatial and temporal cog-
nitive deficits associated with CGG repeat expansions
and the neurological pathology in FXTAS [94]. By con-
trast, enhanced LTD has been reported in the CGGnih
KI mouse model [95]. LTD at CA3-CA1 hippocampal
synapses induced by bath application of the group I
mGluR agonist DHPG was enhanced relative to that
seen in WT littermates. Fmr1 mRNA production was
increased, FMRP translational efficiency in response to
DHPG was impaired, and basal FMRP levels were
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mice completely lacking FMRP also showed enhanced
LTD, suggesting that the enhanced LTD in the CGGnih
KI mouse may be due, at least in part, to lower levels of
FMRP. The differing results for LTD between the
CGGdut and CGGnih KI mouse models may therefore be
the result of small versus moderate reductions in FMRP,
respectively, indicating different cellular mechanisms
for the differing results.
Developmental aspects in FPM and FXTAS
FXTAS was originally described as a late-onset neurode-
generative disorder typically appearing in premutation car-
riers in the fifth or sixth decade of life. However, it is clear
from both human [96,97] and mouse studies [29] that the
consequences of the expanded CGG repeat can be seen in
FPM carriers much earlier in development, indicating that
the disease process likely begins much earlier in life, and
possibly as early as during gestation [98]. Some children
with the premutation have been reported to show cogni-
tive deficits and behavioral problems, including symptoms
of autism spectrum disorder and attention-deficit hyper-
activity disorder [96,97]. Young (<12-week-old) CGGdut
and CGGnih KI mice show impaired processing of spatial
information [29] and abnormal locomotor activity and
anxiety in the elevated Plus-maze [30].
The possibility that the premutation may affect early
brain development is supported by findings in the CGGdut
KI mouse, where abnormal migration and differentiation
of neuronal precursors during development of the embry-
onic cortical plate has been found [98]. In this study, pre-
cursor cells and embryonic neurons were labeled in utero
on embryonic day 14 (E14) by intracerebral injections of a
retrovirus encoding EGFP. The entire cell body, cytoplasm
and processes of infected cells and their progeny were labeled
with the EGFP reporter. The morphology of EGFP-labeled
radial glial cells and immature neurons was not different be-
tween KI andWT neurons when examined on E17. However,
there was evidence for altered differentiation of embryonic
neural progenitor cells in the developing neocortex.
Radial glial cells in the ventricular zone express the
transcription factor Pax6, divide at the ventricular surface
and give rise to intermediate neuronal progenitor cells
that express the transcription factor Tbr2 [99,100]. The
CGGdut KI mice had a greater number of Pax6
+ cells in
the ventricular zone and fewer Tbr2+ cells in the subven-
tricular zone than WT mice, suggesting that delayed dif-
ferentiation of the Pax6 cells in the CGGdut KI mice may
have produced a shift towards more Pax6+ and fewer
Tbr2+ cells. Importantly, the shift in cell distribution could
not be attributed to increased proliferation of Pax6+ cells,
decreased proliferation of Tbr2+ or increased cell death
among Tbr2+ cells. These data suggest that the Fmr1
CGG repeat allele impacts the developing brain duringgestation, much earlier than previously realized, and point
to a neurodevelopmental component in FXTAS.
Neurobehavioral correlates
Key features of patients with FXTAS are late-onset ataxia
and memory impairments. Similar phenotypes have been
found for CGG KI mice. Motor performance on the
rotarod declines with age in CGGdut KI mice [31]. In
addition, sensory-motor coordination is impaired in
adult CGGdut KI animals when they are required to
traverse a horizontal ladder (the ladder rung task). Both
male and female CGGdut KI mice showed impairments
that were positively correlated with CGG repeat size
[101]. Poor performance in the rotarod and ladder rung
test may reflect the ataxia seen in FXTAS. Adult female
CGG KI mice are also impaired in learning a skilled
forelimb motor task, in which they are trained to reach
through a narrow opening in a Plexiglas box to grasp
and obtain a small food reward positioned just outside.
Again, performance was worse with longer CGG repeat
lengths [102]. Similar experiments have not yet been
carried out in male mice. To date, studies in CGG KI
mice have not reported intention tremors, a key neuro-
logical feature in FXTAS. The reason for this is unclear,
but may be related to the quadrupedal organization of
the rodent motor system.
Spatial learning and memory in the Morris water maze
is impaired in CGGdut KI mice at 52 weeks of age, but
not at 20 weeks, indicating a progressive nature of the
deficit [31]. Additional spatial deficits in CGGdut KI mice
are seen in the ‘metric’ spatial processing test, which
involves processing precise angles and distances that
separate objects in space, without regard to the identity
of the objects [103]. In this test, mice are allowed to ex-
plore two identical objects separated in space by a fixed
distance for 15 min (the study phase), showing very little
further exploration at the end of this time. Mice are re-
moved from the apparatus, the distance between the ob-
jects changed (for example, moved closer together), and
the mice are allowed to re-explore the objects for 5 min
(the test phase). During the test phase, WT mice showed
increased object exploration, indicating that they de-
tected a change in the distance between objects, whereas
CGGdut KI mice failed to re-explore the objects. Deficits
in this task were seen as early as 12 weeks of age, when
small but easily detectable intranuclear inclusions
were present in neurons in the dentate gyrus of the hippo-
campus but not in the parietal cortex [29]. Lesion studies
have implicated the dentate gyrus and CA3 hippocampus
in processing of metric spatial information, a form of
spatial pattern separation [104]. This suggests that histo-
pathology (for example, presence of intranuclear inclu-
sions, altered dendritic and spine morphology) in the
dentate gyrus and CA3 subregion of the hippocampus in
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deficit. Although the role of intranuclear inclusions to
pathology in FXTAS is unclear, the presence of intra-
nuclear inclusions in different brain regions at different
ages appears to follow a similar time course as the
emergence of behavioral dysfunction in the CGG KI
mouse, suggesting there might be a relationship
between spatial deficits and inclusion formation
[24,105,106].
Additional behavioral pathology found in the CGGnih
KI mouse model of the FPM and FXTAS includes mild
hyperactivity, decreased anxiety in elevated plus maze,
and impaired shock avoidance learning [30].
Evidence for current disease models
RNA toxicity
Studies in mouse models have been particularly useful in
identifying molecular mechanisms in the FPM and
FXTAS. An RNA ‘toxic gain of function’ mechanism has
been proposed in which elevated FMR1 mRNA tran-
scripts bearing an expanded CGG repeat are cytotoxic.
Toxicity appears to be the result of the expanded CGG
repeat per se, and not of overexpression of FMR1. This
is supported by the fact that ectopic expression of a
CGG repeat expansion in the premutation range is suffi-
cient to induce formation of intranuclear inclusions, reduce
cell viability, trigger neuronal death (for example, Purkinje
cell loss) and produce behavioral deficits [34,59,107],
whereas overexpression of Fmr1 mRNA without a CGG
repeat expansion does not appear to be toxic [41]. Similar
RNA toxicity has been suggested to underlie the path-
ology in several repeat diseases, including the myotonic
muscular dystrophies. In this model, sequestration of
important proteins through their interactions with ex-
panded repeats prevents the proteins from carrying out
their normal functions. As shown in Figure 2A, a similar
protein sequestration mechanism has been proposed to
underlie disease processes in the FPM and in FXTAS
[2,36,82,108]. Based on studies in human and animal
(for example, mouse, fly) tissues, a number of candidate
RNA binding proteins have been identified, including
DGCR8 and DROSHA [47], SAM68 [19], purα [109,110],
hnRNPA2/B1 and CUGBP1 [37].
Sequestration of DROSHA/DGCR8 and miRNAs
While the evidence is strong for the binding of proteins
to CGG expansions and sequestration of proteins within
ubiquitin-positive inclusions, the consequences of seques-
tration for cell function remain to be described. However,
a recent study has linked sequestration of proteins asso-
ciated with miRNA processing with the disease process
in FXTAS [47]. Specifically, the double-stranded RNA-
binding protein DGCR8 binds preferentially to CGG repeats
of pathogenic length (that is, CGG repeat length >60). Asdepicted in Figure 2A, this leads to partial sequestration of
DGCR8 and its binding partner DROSHA to expanded
CGG repeats within CGG RNA aggregates. DGCR8 and
DROSHA are important for processing pre-miRNAs into
mature miRNAs by the DICER enzyme. Dgcr8 deficiency
in heterozygous Dgcr8+/− mice results in reduced syn-
aptic potentiation in layer five pyramidal neurons in the
medial prefrontal cortex of mice [111]. Large deletions
in the 22q11 locus, which include Dgcr8, result in
altered dendritic spine morphology, reduced dendritic
branching complexity and impaired working memory
[112]. Similarly, loss of DICER in mice results in pro-
gressive neuronal degeneration [113], reduced dendritic
branching and increased dendritic spine length [114],
ataxia, and reduced brain size following deletion from
striatal neurons [115]. These results suggested a model
in which double-stranded CGG RNA forms hairpins
[91] that mimic the RNA structure of pre-miRNAs recog-
nized by DGCR8 [47]. DGCR8 and its partner DROSHA
bind to the expanded CGG repeat element and are there-
fore sequestered, reducing the production of mature miR-
NAs causing neuronal dysfunction and death [47]. This
possibility is supported by the observation that the expres-
sion of mature miRNAs was decreased in postmortem
brain samples from patients with FXTAS. In addition,
in vitro overexpression of DGCR8 restored normal den-
dritic growth and branching, and alleviated cell death of
cultured neurons expressing a toxic 60 CGG repeat [47].
Repeat associated non-AUG translation
An additional mechanism of toxicity is shown in Figure 2B.
In this model, toxicity is triggered by CGG RAN transla-
tion [20]. This is based on evidence that trinucleotide
repeats can be translated into protein even if they do not
reside in an AUG-initiated open reading frame [116], and
such translation can occur in all three possible open read-
ing frames of a transcript generating multiple potentially
toxic products from a single repeat [117]. In the case of
FXTAS, it has been proposed that RAN translation initi-
ated in the 5′UTR of FMR1 mRNA results in the produc-
tion of a cytotoxic polyglycine-containing protein named
FMRpolyG [20]. This is supported by results from human
FXTAS and animal model studies. Specifically, the pres-
ence of the FMRpolyG was confirmed by western blot in
cerebellar lysates of postmortem FXTAS brains. FMRpo-
lyG staining was specific for FXTAS, and was not found in
control brains, or in brain sections from patients with spi-
nocerebellar ataxia type 3 or Alzheimer’s disease. Interest-
ingly, there were clear differences between the CGGdut KI
and CGGnih KI mouse models, with co-localization of
FMRpolyG and ubiquitin-positive intranuclear inclusions
in the cortex and hypothalamus of the CGGdut KI mouse,
but not in the CGGnih KI mouse. These data suggest that
some of the differing pathology between the two mouse
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generate the toxic polyglycine peptide. The mechanisms
underlying RAN translation are as yet unknown, but the
presence of the polyglycine peptide (that is, FMRpolyG) in
FXTAS and the CGG KI mouse models led to the
proposal by Todd et al. that a scanning 43S ribosomal
pre-initiation complex stalls at the CGG repeat, resulting
in use of an alternative non-AUG start site for translation
in the +1 reading frame (that is, GGC, polyglycine) and
the production of the FMRpolyG protein. The data did
not show translation product from the +0 (that is, CGG,
polyarginine) reading frame, but some, albeit less efficient,
translation in the +2 (that is, GCG, polyalanine) reading
frame was observed [20].Conclusions
Although uniquely human components of disease cannot
be fully captured in other species, mouse models of
FXTAS have provided useful research tools to test hypoth-
eses about the causes of the disorder, and to discover
effective treatments. Development of CGG KI mice has
provided insight into the natural history of the disorder,
the molecular correlates, hallmark pathology in the brain
and other organ systems, as well as an understanding of
the neurobehavioral effects of expression of CGG repeat
expansions. These KI mice now allow for the evaluation of
novel therapeutic strategies, whether pharmacological or
gene-targeted, to halt or reverse disease processes and to
improve neurological outcome. Ongoing development of
new mouse lines, including conditional and inducible
mice, should further increase the value of animal models
to understand the pathology of repeat disorders such as
FXTAS. There are many open questions to be answered
that will continue to rely on mouse models, including why
mRNA levels are elevated, the importance of reduced
FMRP in pathology, whether intranuclear inclusions are
toxic or simply mark the progress of disease, and how
protein sequestration and RAN translation contribute to
the disease process in FPM and FXTAS.Abbreviations
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